Actively Recruiting
Brain Circuitry Therapeutics for Schizophrenia
Led by Indrit Begue · Updated on 2024-11-19
70
Participants Needed
2
Research Sites
190 weeks
Total Duration
On this page
Sponsors
I
Indrit Begue
Lead Sponsor
U
University of Geneva, Switzerland
Collaborating Sponsor
AI-Summary
What this Trial Is About
This project is a double blind randomized clinical trials that examines the efficacy of cerebellar non invasive stimulation for apathy improvement in patients with schizophrenia
CONDITIONS
Official Title
Brain Circuitry Therapeutics for Schizophrenia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Capable of giving informed consent as evaluated by the treating psychiatrist
- Signed informed consent
- Age between 18 and 65 years
- Diagnosed with a schizophrenia spectrum disorder (schizophrenia, schizoaffective, non-organic psychosis, psychotic disorder NOS) by DSM-5 criteria
- Clinically stable condition as judged by treating psychiatrist
- Antipsychotic treatments unchanged for at least 4 weeks
- No hospitalization in acute psychiatry ward within 3 months prior to study entry
You will not qualify if you...
- Current major depressive episode diagnosed by treating psychiatrist
- Active psychotic symptoms with PANSS scores above 4 in delusions, suspiciousness, or hallucinatory behavior
- Significant extrapyramidal side effects with mSAS score over 12
- Increased sedation from medication
- Active daily substance use including therapeutic drugs like methadone
- History of fainting spells that might be seizures
- History of multiple seizures or epilepsy
- Progressive neurological disorders such as multiple sclerosis or Parkinson's disease
- Chronic uncontrolled medical conditions that risk emergency during seizure
- Presence of metallic implants excluding dental fillings unless MRI compatible
- Implants controlled by physiological signals in or near the head (e.g., pacemaker, implanted pumps, vagal nerve stimulators, deep brain stimulators, ventriculo-peritoneal shunt, cochlear implant)
- Impaired heat or pain sensation or open wounds
- Increased intracranial pressure
- Intracranial lesions from genetic or acquired neurologic diseases
- History of head injury with prolonged loss of consciousness over 15 minutes or neurological sequelae
- Pregnancy or breastfeeding; active contraception required for those who can become pregnant
- Significant concomitant diseases (renal failure, hepatic dysfunction, cardiovascular disease, cancer, pulmonary decompensation)
- Inability to follow study procedures due to language, psychological, intellectual, or cognitive issues
- Legal obligation for psychiatric treatment
- Participation in another investigational drug or device study within 30 days or currently
- Previous enrollment in this study
- Investigator or related personnel enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Campus Biotech
Geneva, Switzerland, 1202
Actively Recruiting
2
Indrit Bègue
Geneva, Switzerland, 1202
Not Yet Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here